PATANOL ® (olopatadine hydrochloride ophthalmic solution) 0.1%

Manufacturer
Alcon Laboratories, Inc.
Effective date
2020-10-08
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
10
Source
legacy-cache
Hydrated at
2026-08-01 23:12:36

Label at a glance#

ProductPatanol
Active ingredientOLOPATADINE HYDROCHLORIDE
Label structure9 sections

Indications and uses

PATANOL ® (olopatadine hydrochloride ophthalmic solution) 0.1% is indicated for the treatment of the signs and symptoms of allergic conjunctivitis.

Dosage and administration

The recommended dose is one drop in each affected eye two times per day at an interval of 6 to 8 hours.

Label contents#

Full prescribing information#

DESCRIPTION

DESCRIPTION SECTION

PATANOL® (olopatadine hydrochloride ophthalmic solution) 0.1% is a sterile ophthalmic solution containing olopatadine, a relatively selective H1-receptor antagonist and inhibitor of histamine release from the mast cell for topical administration to the eyes. Olopatadine hydrochloride is a white, crystalline, water-soluble powder with a molecular weight of 373.88. The chemical structure is presented below:

Chemical Name: 11-[(Z)-3-(Dimethylamino)propylidene]-6-11-dihydrodibenz[b,e] oxepin-2-acetic acid hydrochloride

chemical
chemical

Each mL of PATANOL (olopatadine hydrochloride ophthalmic solution) 0.1% contains: Active: 1.11 mg olopatadine hydrochloride equivalent to 1 mg olopatadine. Preservative: benzalkonium chloride 0.01%. Inactives: dibasic sodium phosphate; sodium chloride; hydrochloric acid/sodium hydroxide (adjust pH); and purified water. It has a pH of approximately 7 and an osmolality of approximately 300 mOsm/kg.

CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

Olopatadine is an inhibitor of the release of histamine from the mast cell and a relatively selective histamine H1-receptor antagonist that inhibits the in vivo and in vitro type 1 immediate hypersensitivity reaction, including inhibition of histamine induced effects on human conjunctival epithelial cells. Olopatadine is devoid of effects on alpha-adrenergic, dopamine and muscarinic type 1 and 2 receptors. Following topical ocular administration in man, olopatadine was shown to have low systemic exposure. Two studies in normal volunteers (totaling 24 subjects) dosed bilaterally with olopatadine 0.15% ophthalmic solution once every 12 hours for 2 weeks demonstrated plasma concentrations to be generally below the quantitation limit of the assay (< 0.5 ng/mL). Samples in which olopatadine was quantifiable were typically found within 2 hours of dosing and ranged from 0.5 to 1.3 ng/mL. The half-life in plasma was approximately 3 hours, and elimination was predominantly through renal excretion. Approximately 60%-70% of the dose was recovered in the urine as parent drug. Two metabolites, the mono-desmethyl and the N-oxide, were detected at low concentrations in the urine.

Results from an environmental study demonstrated that PATANOL was effective in the treatment of the signs and symptoms of allergic conjunctivitis when dosed twice daily for up to 6 weeks. Results from conjunctival antigen challenge studies demonstrated that PATANOL, when subjects were challenged with antigen both initially and up to 8 hours after dosing, was significantly more effective than its vehicle in preventing ocular itching associated with allergic conjunctivitis.

INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

PATANOL® (olopatadine hydrochloride ophthalmic solution) 0.1% is indicated for the treatment of the signs and symptoms of allergic conjunctivitis.

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

PATANOL® (olopatadine hydrochloride ophthalmic solution) 0.1% is contraindicated in persons with a known hypersensitivity to olopatadine hydrochloride or any components of PATANOL.

WARNINGS

PATANOL® (olopatadine hydrochloride ophthalmic solution) 0.1% is for topical use only and not for injection or oral use.

PRECAUTIONS

PRECAUTIONS SECTION

INFORMATION FOR PATIENTS SECTION

Information for Patients: To prevent contaminating the dropper tip and solution, care should be taken not to touch the eyelids or surrounding areas with the dropper tip of the bottle. Keep bottle tightly closed when not in use.

Patients should be advised not to wear a contact lens if their eye is red. PATANOL® (olopatadine hydrochloride ophthalmic solution) 0.1% should not be used to treat contact lens related irritation. The preservative in PATANOL, benzalkonium chloride, may be absorbed by soft contact lenses. Patients who wear soft contact lenses and whose eyes are not red should be instructed to wait at least ten minutes after instilling PATANOL® (olopatadine hydrochloride ophthalmic solution) 0.1% before they insert their contact lenses.

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION

Carcinogenesis, Mutagenesis, Impairment of Fertility: Olopatadine administered orally was not carcinogenic in mice and rats in doses up to 500 mg/kg/day and 200 mg/kg/day, respectively. Based on a 40 μL drop size, these doses were 78,125 and 31,250 times higher than the maximum recommended ocular human dose (MROHD). No mutagenic potential was observed when olopatadine was tested in an in vitro bacterial reverse mutation (Ames) test, an in vitro mammalian chromosome aberration assay or an in vivo mouse micronucleus test. Olopatadine administered to male and female rats at oral doses of 62,500 times MROHD level resulted in a slight decrease in the fertility index and reduced implantation rate; no effects on reproductive function were observed at doses of 7,800 times the maximum recommended ocular human use level.

PREGNANCY SECTION

Pregnancy: Olopatadine was found not to be teratogenic in rats and rabbits. However, rats treated at 600 mg/kg/day, or 93,750 times the MROHD and rabbits treated at 400 mg/kg/day, or 62,500 times the MROHD, during organogenesis showed a decrease in live fetuses. There are, however, no adequate and well controlled studies in pregnant women. Because animal studies are not always predictive of human responses, this drug should be used in pregnant women only if the potential benefit to the mother justifies the potential risk to the embryo or fetus.

LACTATION SECTION

Nursing Mothers: Olopatadine has been identified in the milk of nursing rats following oral administration. It is not known whether topical ocular administration could result in sufficient systemic absorption to produce detectable quantities in the human breast milk. Nevertheless, caution should be exercised when PATANOL® (olopatadine hydrochloride ophthalmic solution) 0.1% is administered to a nursing mother.

PEDIATRIC USE SECTION

Pediatric Use: Safety and effectiveness in pediatric patients below the age of 3 years have not been established.

GERIATRIC USE SECTION

Geriatric Use: No overall differences in safety or effectiveness have been observed between elderly and younger patients.

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

Headaches have been reported at an incidence of 7%. The following adverse experiences have been reported in less than 5% of patients: asthenia, blurred vision, burning or stinging, cold syndrome, dry eye, foreign body sensation, hyperemia, hypersensitivity, keratitis, lid edema, nausea, pharyngitis, pruritus, rhinitis, sinusitis, and taste perversion. Some of these events were similar to the underlying disease being studied.

DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

The recommended dose is one drop in each affected eye two times per day at an interval of 6 to 8 hours.

HOW SUPPLIED

HOW SUPPLIED SECTION

PATANOL® (olopatadine hydrochloride ophthalmic solution) 0.1% is supplied as follows:
5 mL in plastic DROP-TAINER® dispenser.

5 mL:                                                NDC 0065-0271-05

Storage: Store at 4°C-25°C (39°F-77°F)

Rx Only

© 2000, 2003, 2007, 2018 Novartis


Distributed by:

ALCON LABORATORIES, INC.

Fort Worth, Texas 76134


Alcon®

A Novartis company


Revised: April 2018

T2018-48

PRINCIPAL DISPLAY PANEL

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC 0065-0271-05

Alcon®

Patanol®

(olopatadine

hydrochloride

ophthalmic

solution) 0.1%

5 mL Sterile

carton
carton

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
0065-0271-05ML - Milliliter0065-0271fbac5306-f0bc-4f14-a94c-3d57a7e0baaf12012-07-24

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
IngredientTypeUNIISPL versionUploaded
OLOPATADINE HYDROCHLORIDEACTIVE INGREDIENT2XG66W44KF5
OLOPATADINEACTIVE MOIETYD27V6190PM5
BENZALKONIUM CHLORIDEINACTIVE INGREDIENTF5UM2KM3W75
HYDROCHLORIC ACIDINACTIVE INGREDIENTQTT17582CB5
SODIUM CHLORIDEINACTIVE INGREDIENT451W47IQ8X5
SODIUM HYDROXIDEINACTIVE INGREDIENT55X04QC32I5
SODIUM PHOSPHATE, DIBASICINACTIVE INGREDIENTGR686LBA745
WATERINACTIVE INGREDIENT059QF0KO0R5

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 9 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
0065-02710065-0271-05

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 7 matching rows.

Source Document#

Source XML

Inactive ingredient matches#

Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.

Inactive ingredient links page 1 of 9 · 494 matching rows.

DailyMed ingredient, IID ingredient, UNII table
DailyMed ingredientIID ingredientUNIIDosage form / routePotencyMaximum daily exposureMatch
SODIUM CHLORIDESODIUM CHLORIDE451W47IQ8XSUSPENSION / TOPICAL0.32 %w/vExact identifier — unii candidate
134 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION, SUSPENSION, LIPOSOMAL / INTRAVENOUSADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
HYDROCHLORIC ACIDHYDROCHLORIC ACIDQTT17582CBSUSPENSION/ DROPS / TOPICALADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
SODIUM CHLORIDESODIUM CHLORIDE451W47IQ8XINJECTION / EPIDURAL648 mgExact identifier — unii candidate
134 equally ranked IID candidates
HYDROCHLORIC ACIDHYDROCHLORIC ACIDQTT17582CBCONCENTRATE / ORAL2.17 mg/1mlExact identifier — unii candidate
148 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ISOLUTION / URETERALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
HYDROCHLORIC ACIDHYDROCHLORIC ACIDQTT17582CBSOLUTION / SUBCUTANEOUSADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
SODIUM CHLORIDESODIUM CHLORIDE451W47IQ8XTABLET / ORAL231 mgExact identifier — unii candidate
134 equally ranked IID candidates
HYDROCHLORIC ACIDHYDROCHLORIC ACIDQTT17582CBSUSPENSION / AURICULAR (OTIC)0.04 %w/vExact identifier — unii candidate
148 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IMOUTHWASH / BUCCAL2 mg/1mlExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM CHLORIDESODIUM CHLORIDE451W47IQ8XINJECTION / INTRAMUSCULAR1486 mgExact identifier — unii candidate
134 equally ranked IID candidates
BENZALKONIUM CHLORIDEBENZALKONIUM CHLORIDEF5UM2KM3W7SOLUTION / AURICULAR (OTIC)0.01 %w/vExact identifier — unii candidate
24 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION / EPIDURALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
HYDROCHLORIC ACIDHYDROCHLORIC ACIDQTT17582CBINJECTION, POWDER, FOR SOLUTION / INTRATUMORADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
HYDROCHLORIC ACIDHYDROCHLORIC ACIDQTT17582CBSPONGE / TOPICALADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION / INTRALESIONALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ISOLUTION / INTRATHECALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
HYDROCHLORIC ACIDHYDROCHLORIC ACIDQTT17582CBINJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAVENOUS160 mgExact identifier — unii candidate
148 equally ranked IID candidates
SODIUM CHLORIDESODIUM CHLORIDE451W47IQ8XINJECTION, SOLUTION / PARENTERAL210 mgExact identifier — unii candidate
134 equally ranked IID candidates
SODIUM CHLORIDESODIUM CHLORIDE451W47IQ8XINJECTION / INTRASYNOVIAL0.9 %w/vExact identifier — unii candidate
134 equally ranked IID candidates
SODIUM CHLORIDESODIUM CHLORIDE451W47IQ8XSUPPOSITORY / RECTAL140 mgExact identifier — unii candidate
134 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION, SUSPENSION / INTRASYNOVIALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION / SUBCUTANEOUS31.45 mgExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM PHOSPHATE, DIBASICSODIUM PHOSPHATE, DIBASICGR686LBA74INJECTION / SUBCUTANEOUS14 mgExact identifier — unii candidate
14 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION, SUSPENSION / INTRAMUSCULARADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION, SOLUTION / SUBARACHNOIDADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ITABLET, FILM COATED / ORAL8 mgExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ISOLUTION / IRRIGATIONADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ILOTION, AUGMENTED / TOPICALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM CHLORIDESODIUM CHLORIDE451W47IQ8XSOLUTION/ DROPS / OPHTHALMIC55 mgExact identifier — unii candidate
134 equally ranked IID candidates
SODIUM CHLORIDESODIUM CHLORIDE451W47IQ8XLOTION / TOPICAL0.3 %w/vExact identifier — unii candidate
134 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IPASTE / DENTAL0.6 %w/wExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM CHLORIDESODIUM CHLORIDE451W47IQ8XINJECTION / INTRAVASCULAR0.86 %w/vExact identifier — unii candidate
134 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ITABLET, ORALLY DISINTEGRATING / ORAL1 mgExact identifier — unii candidate
174 equally ranked IID candidates
HYDROCHLORIC ACIDHYDROCHLORIC ACIDQTT17582CBINJECTION / INTRAMUSCULAR306 mgExact identifier — unii candidate
148 equally ranked IID candidates
SODIUM CHLORIDESODIUM CHLORIDE451W47IQ8XINJECTION, SUSPENSION / SUBCUTANEOUS0.8 %w/vExact identifier — unii candidate
134 equally ranked IID candidates
HYDROCHLORIC ACIDHYDROCHLORIC ACIDQTT17582CBCREAM / TOPICAL38 mgExact identifier — unii candidate
148 equally ranked IID candidates
SODIUM PHOSPHATE, DIBASICSODIUM PHOSPHATE, DIBASICGR686LBA74FILM, SOLUBLE / ORAL9 mgExact identifier — unii candidate
14 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION, POWDER, FOR SOLUTION / INTRAMUSCULAR7.01 mgExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM CHLORIDESODIUM CHLORIDE451W47IQ8XINJECTION, SOLUTION, CONCENTRATE / SUBCUTANEOUS0.86 %w/vExact identifier — unii candidate
134 equally ranked IID candidates
HYDROCHLORIC ACIDHYDROCHLORIC ACIDQTT17582CBINJECTION / SOFT TISSUEADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
HYDROCHLORIC ACIDHYDROCHLORIC ACIDQTT17582CBINJECTION, SOLUTION / INFILTRATIONADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION, SOLUTION / SUBCUTANEOUS1 %w/vExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ISUSPENSION, EXTENDED RELEASE / INTRALESIONALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM CHLORIDESODIUM CHLORIDE451W47IQ8XPOWDER, FOR SUSPENSION / ENDOTRACHEAL46.76 mgExact identifier — unii candidate
134 equally ranked IID candidates
SODIUM CHLORIDESODIUM CHLORIDE451W47IQ8XINJECTION / INTRAVENOUS28773 mgExact identifier — unii candidate
134 equally ranked IID candidates
SODIUM CHLORIDESODIUM CHLORIDE451W47IQ8XPOWDER, DENTIFRICE / DENTAL0.03 mg/mgExact identifier — unii candidate
134 equally ranked IID candidates
HYDROCHLORIC ACIDHYDROCHLORIC ACIDQTT17582CBSOLUTION / INTRA-ARTERIALADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ILOTION / TOPICAL21 mgExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM CHLORIDESODIUM CHLORIDE451W47IQ8XINJECTION, SOLUTION / INTRAVENOUS2916 mgExact identifier — unii candidate
134 equally ranked IID candidates
SODIUM CHLORIDESODIUM CHLORIDE451W47IQ8XINJECTION, POWDER, FOR SOLUTION / INTRA-ARTERIAL1.35 mgExact identifier — unii candidate
134 equally ranked IID candidates
SODIUM CHLORIDESODIUM CHLORIDE451W47IQ8XINJECTION / INTRABURSAL9 mgExact identifier — unii candidate
134 equally ranked IID candidates
SODIUM CHLORIDESODIUM CHLORIDE451W47IQ8XINJECTION, POWDER, FOR SUSPENSION / SUBCUTANEOUSNAExact identifier — unii candidate
134 equally ranked IID candidates
HYDROCHLORIC ACIDHYDROCHLORIC ACIDQTT17582CBINJECTION / INTRA-AMNIOTICADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
SODIUM CHLORIDESODIUM CHLORIDE451W47IQ8XINJECTION / INTRATUMOR1.2 %w/vExact identifier — unii candidate
134 equally ranked IID candidates
HYDROCHLORIC ACIDHYDROCHLORIC ACIDQTT17582CBINJECTION, POWDER, FOR SOLUTION / PARENTERALADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
SODIUM CHLORIDESODIUM CHLORIDE451W47IQ8XSUSPENSION / SUBCUTANEOUS0.8 %w/vExact identifier — unii candidate
134 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IPOWDER, FOR SUSPENSION / ORAL9 mgExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM CHLORIDESODIUM CHLORIDE451W47IQ8XINJECTION, SOLUTION / SUBARACHNOID0.9 %w/vExact identifier — unii candidate
134 equally ranked IID candidates
SODIUM CHLORIDESODIUM CHLORIDE451W47IQ8XINJECTION, SOLUTION / SUBCUTANEOUS1486 mgExact identifier — unii candidate
134 equally ranked IID candidates

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 43.

Orange Book products#

Current product rows page 1 of 1 · 1 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
N020688-001PATADAY TWICE DAILY RELIEFOLOPATADINE HYDROCHLORIDEEQ 0.1% BASESOLUTION/DROPS / OPHTHALMICRLD, RS1996-12-18

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 2 · 43 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-09-14 22:38:342026-08N020688-001PATADAY TWICE DAILY RELIEFEQ 0.1% BASESOLUTION/DROPS / OPHTHALMICRLD, RS1996-12-1884e616aacf4f…
2026-08-18 06:07:402026-07N020688-001PATADAY TWICE DAILY RELIEFEQ 0.1% BASESOLUTION/DROPS / OPHTHALMICRLD, RS1996-12-18caaa826d4ba7…
2026-02-19 14:30 UTC2026-02N020688-001PATADAY TWICE DAILY RELIEFEQ 0.1% BASESOLUTION/DROPS / OPHTHALMICRLD, RS1996-12-18011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12N020688-001PATADAY TWICE DAILY RELIEFEQ 0.1% BASESOLUTION/DROPS / OPHTHALMICRLD, RS1996-12-1831067a03dcf5…
2025-08-23 18:47 UTC2025-08N020688-001PATADAY TWICE DAILY RELIEFEQ 0.1% BASESOLUTION/DROPS / OPHTHALMICRLD, RS1996-12-186a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03N020688-001PATADAY TWICE DAILY RELIEFEQ 0.1% BASESOLUTION/DROPS / OPHTHALMICRLD, RS1996-12-18fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02N020688-001PATADAY TWICE DAILY RELIEFEQ 0.1% BASESOLUTION/DROPS / OPHTHALMICRLD, RS1996-12-18b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01N020688-001PATADAY TWICE DAILY RELIEFEQ 0.1% BASESOLUTION/DROPS / OPHTHALMICRLD, RS1996-12-1803ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12N020688-001PATADAY TWICE DAILY RELIEFEQ 0.1% BASESOLUTION/DROPS / OPHTHALMICRLD, RS1996-12-182680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09N020688-001PATADAY TWICE DAILY RELIEFEQ 0.1% BASESOLUTION/DROPS / OPHTHALMICRLD, RS1996-12-185bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11N020688-001PATADAY TWICE DAILY RELIEFEQ 0.1% BASESOLUTION/DROPS / OPHTHALMICRLD, RS1996-12-18d8e5a09893c0…
2024-10-29 15:01 UTC2024-10N020688-001PATADAY TWICE DAILY RELIEFEQ 0.1% BASESOLUTION/DROPS / OPHTHALMICRLD, RS1996-12-18d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08N020688-001PATADAY TWICE DAILY RELIEFEQ 0.1% BASESOLUTION/DROPS / OPHTHALMICRLD, RS1996-12-1879d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07N020688-001PATADAY TWICE DAILY RELIEFEQ 0.1% BASESOLUTION/DROPS / OPHTHALMICRLD, RS1996-12-18301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06N020688-001PATADAY TWICE DAILY RELIEFEQ 0.1% BASESOLUTION/DROPS / OPHTHALMICRLD, RS1996-12-181e350fbaab3a…
2024-05-31 18:47 UTC2024-05N020688-001PATADAY TWICE DAILY RELIEFEQ 0.1% BASESOLUTION/DROPS / OPHTHALMICRLD, RS1996-12-188072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06N020688-001PATADAY TWICE DAILY RELIEFEQ 0.1% BASESOLUTION/DROPS / OPHTHALMICRLD, RS1996-12-185c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04N020688-001PATADAY TWICE DAILY RELIEFEQ 0.1% BASESOLUTION/DROPS / OPHTHALMICRLD, RS1996-12-185d02ea3f76ae…
2022-04-04 05:41 UTC2022-04N020688-001PATADAY TWICE DAILY RELIEFEQ 0.1% BASESOLUTION/DROPS / OPHTHALMICRLD, RS1996-12-184b0b4de00fa7…
2019-12-13 00:20 UTC2019-12N020688-001PATANOLEQ 0.1% BASESOLUTION/DROPS / OPHTHALMICATRLD, RS1996-12-1874a2ff9319b5…
2022-03-09 01:35 UTC2022-03N020688-001PATADAY TWICE DAILY RELIEFEQ 0.1% BASESOLUTION/DROPS / OPHTHALMICRLD, RS1996-12-18bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12N020688-001PATADAY TWICE DAILY RELIEFEQ 0.1% BASESOLUTION/DROPS / OPHTHALMICRLD, RS1996-12-18782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05N020688-001PATADAY TWICE DAILY RELIEFEQ 0.1% BASESOLUTION/DROPS / OPHTHALMICRLD, RS1996-12-1887673890dc5c…
2021-03-12 10:30 UTC2021-03N020688-001PATADAY TWICE DAILY RELIEFEQ 0.1% BASESOLUTION/DROPS / OPHTHALMICRLD, RS1996-12-185aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12N020688-001PATADAY TWICE DAILY RELIEFEQ 0.1% BASESOLUTION/DROPS / OPHTHALMICRLD, RS1996-12-188869cabd3fbd…
2020-11-12 02:37 UTC2020-11N020688-001PATADAY TWICE DAILY RELIEFEQ 0.1% BASESOLUTION/DROPS / OPHTHALMICRLD, RS1996-12-18c0c555d07b60…
2019-12-14 00:12 UTC2019-12N020688-001PATANOLEQ 0.1% BASESOLUTION/DROPS / OPHTHALMICATRLD, RS1996-12-183f01610625f2…
2019-09-15 20:21 UTC2019-09N020688-001PATANOLEQ 0.1% BASESOLUTION/DROPS / OPHTHALMICATRLD, RS1996-12-18b00525d2431f…
2019-07-19 19:46 UTC2019-07N020688-001PATANOLEQ 0.1% BASESOLUTION/DROPS / OPHTHALMICATRLD, RS1996-12-18ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03N020688-001PATADAY TWICE DAILY RELIEFEQ 0.1% BASESOLUTION/DROPS / OPHTHALMICRLD, RS1996-12-186a51e52b5d6a…
2024-02-18 07:12 UTC2024-02N020688-001PATADAY TWICE DAILY RELIEFEQ 0.1% BASESOLUTION/DROPS / OPHTHALMICRLD, RS1996-12-181c564ffb4f44…
2023-12-20 04:57 UTC2023-12N020688-001PATADAY TWICE DAILY RELIEFEQ 0.1% BASESOLUTION/DROPS / OPHTHALMICRLD, RS1996-12-18ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11N020688-001PATADAY TWICE DAILY RELIEFEQ 0.1% BASESOLUTION/DROPS / OPHTHALMICRLD, RS1996-12-18a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10N020688-001PATADAY TWICE DAILY RELIEFEQ 0.1% BASESOLUTION/DROPS / OPHTHALMICRLD, RS1996-12-189b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07N020688-001PATADAY TWICE DAILY RELIEFEQ 0.1% BASESOLUTION/DROPS / OPHTHALMICRLD, RS1996-12-18a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06N020688-001PATADAY TWICE DAILY RELIEFEQ 0.1% BASESOLUTION/DROPS / OPHTHALMICRLD, RS1996-12-183f0d92c62455…
2023-05-13 08:27 UTC2023-05N020688-001PATADAY TWICE DAILY RELIEFEQ 0.1% BASESOLUTION/DROPS / OPHTHALMICRLD, RS1996-12-18053a50430f4f…
2023-01-26 05:58 UTC2023-01N020688-001PATADAY TWICE DAILY RELIEFEQ 0.1% BASESOLUTION/DROPS / OPHTHALMICRLD, RS1996-12-183bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11N020688-001PATADAY TWICE DAILY RELIEFEQ 0.1% BASESOLUTION/DROPS / OPHTHALMICRLD, RS1996-12-183a93d1ddd44b…
2022-10-28 04:53 UTC2022-10N020688-001PATADAY TWICE DAILY RELIEFEQ 0.1% BASESOLUTION/DROPS / OPHTHALMICRLD, RS1996-12-18f41ea6bd6efb…

Observed Orange Book normalized TE history#

Captured, Edition, Application-product table
CapturedEditionApplication-productTE codeOrderSource SHA-256
2019-12-13 00:20 UTC2019-12N020688-001AT174a2ff9319b5…
2019-12-14 00:12 UTC2019-12N020688-001AT13f01610625f2…
2019-09-15 20:21 UTC2019-09N020688-001AT1b00525d2431f…
2019-07-19 19:46 UTC2019-07N020688-001AT1ea99ee380514…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
144a0240-0655-4a63-aee2-e6d4e563a378eae41728-12e3-4bde-a6bb-b384a5cbae412020-10-08Adverse reactionsExact identifier
spl id: 144a0240-0655-4a63-aee2-e6d4e563a378
spl set id: eae41728-12e3-4bde-a6bb-b384a5cbae41

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.